For the latest updates on our ongoing response to COVID-19, please click here.

Medicine Questions
Investors
Contact

North America

South America

Asia

Middle East

Africa

Australia

Europe

Newsroom

An Open Letter from Daniel O’Day, Chairman & CEO, Gilead Sciences

An update about our investigational antiviral for the treatment of COVID-19.

Daniel O’Day - June 29, 2020

Recent Story Posts

Community

Four Questions with Cleve Jones: Reflecting on the AIDS Memorial Quilt as it Returns Home

Stories@Gilead - July 08, 2020
Innovation

Four Questions with Gilead’s Virology Clinical Research Team: Continuing to Pursue Transformational Innovation in HIV

Stories@Gilead - July 06, 2020
Culture

Taking Care of Those Who Are Left Out and Left Behind

Rashad Burgess - June 30, 2020

Recent Press Releases

Explore More

View Upcoming Events

Company Statements

2019 Year in Review

 

For more information, contact us.

Phone:
1-800-GILEAD-5 (1-800-445-3235) 1-800-GILEAD-5 (1-800-445-3235)

Email:
public_affairs@gilead.com